Fosun Pharma: all 194 studies

Page 2 of 2. Open to participants first (81), then studies with results posted, then the rest; newest registration first within each.

• Mass Balance Study of [14C]HLX208 in China Healthy SubjectsCompletedNCT05841940Phase 1
• A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC PatientsActive, not recruitingNCT05787613Phase 2
• Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in InfantsActive, not recruitingNCT05759520Phase 3
• Evaluate Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19 in ChinaStatus unknownNCT05682599Phase 2
• A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male SubjectsCompletedNCT05679258Phase 1
• Real-world Study Evaluating the Efficacy and Safety of Azvudine in Nursing Home PatientsStatus unknownNCT05675748
• Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19Status unknownNCT05633433Phase 2/3
• A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or LymphomaActive, not recruitingNCT05606380Phase 1
• Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRCTerminatedNCT05584137Phase 2
• Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPCActive, not recruitingNCT05513573Phase 2
• A Study to Investigate the Safety, Tolerability and Efficacy of HLX60 Combination With HLX10 in Subjects With Advanced or Metastatic Solid TumorsActive, not recruitingNCT05483530Phase 1
• To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLCActive, not recruitingNCT05468489Phase 3
• Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult VolunteersWithdrawnNCT05429385Phase 1
• Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid TumorCompletedNCT05400265Phase 1
• A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid TumorsActive, not recruitingNCT05394168Phase 1
• A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or LymphomaStatus unknownNCT05390528Phase 1/2
• HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid TumorsActive, not recruitingNCT05360381Phase 1
• HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid TumorsStatus unknownNCT05360368Phase 1
• A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung CancerStatus unknownNCT05354700Phase 2
• A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung CancerActive, not recruitingNCT05353257Phase 3
• A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of FractureCompletedNCT05352516Phase 3
• A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast CancerActive, not recruitingNCT05346224Phase 3
• HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular CarcinomaStatus unknownNCT05290220Phase 2
• HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric CancerStatus unknownNCT05246982Phase 2
• The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)Status unknownNCT05238363Phase 2
• A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR ExpressionStatus unknownNCT05215925Phase 2
• Study of FCN-098 in Patients With Advanced Solid TumorStatus unknownNCT05212987Phase 1
• Treatment of Patients With Advanced Solid Tumors With Oral Agent ORIN1001 and in Combination With Standard of Care.CompletedNCT05154201Phase 1/2
• The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E MutationActive, not recruitingNCT05127759Phase 2
• A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 MutationStatus unknownNCT05114603Phase 2
• The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 MutationActive, not recruitingNCT05102292Phase 1/2
• HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid TumorsStatus unknownNCT05102214Phase 1/2
• The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E MutationActive, not recruitingNCT05092815Phase 2
• The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line TreatmentStatus unknownNCT05092802Phase 2
• A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or LymphomaCompletedNCT05078593Phase 1
• A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 MutationStatus unknownNCT05065398Phase 2
• Assessment of Cellular and Tissue Characteristics in Lipoaspirates Stirred by VorFatWithdrawnNCT05016674Not applicable
• Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMDCompletedNCT05003245Phase 3
• Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMDCompletedNCT04993352Phase 1/2
• The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line TreatmentActive, not recruitingNCT04984369Phase 2
• A Study of HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLCStatus unknownNCT04976647Phase 2
• Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1Active, not recruitingNCT04954001Phase 1/2
• Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric CancerActive, not recruitingNCT04908813Phase 2
• A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical CancerWithdrawnNCT04806945Phase 3
• A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid TumorWithdrawnNCT04797468Phase 1
• A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMDCompletedNCT04740671Phase 3
• Study of FCN-011 in Patients With Advanced Solid Tumor（Phase I）and NTRK Fusion Positive Advanced Solid Tumor （Phase II）Status unknownNCT04687423Phase 1
• A Study of FCN-338 in Patients With Chronic CLL/SLLActive, not recruitingNCT04682808Phase 1
• Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma.WithdrawnNCT04671420Phase 3
• A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(US-licensed and EU-approved) in Healthy Chinese Male SubjectsCompletedNCT04670796Phase 1
• Evaluation of Oral ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)SuspendedNCT04643769Phase 1
• The Efficacy of the Alma Hybrid System for a New Approach of Facial Skin TreatmentCompletedNCT04640207Not applicable
• A Safety and Tolerability Study of FCN-207 in Healthy VolunteersCompletedNCT04622124Phase 1
• The Trio Laser Module for Hair Removal TreatmentCompletedNCT04599751Not applicable
• Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX14 Versus Prolia® in Healthy Male SubjectsCompletedNCT04534582Phase 1
• Single Band vs. Dual Band Pulsed Light Technology for the Treatment of Photodamage - A Split Face Comparison StudyCompletedNCT04519736Not applicable
• Laser 360iQ: Optimal Light-laser Combination TherapyCompletedNCT04519723Not applicable
• A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCCWithdrawnNCT04465734Phase 3
• Compare Pharmacokinetics, Safety, and Immunogenicity of HLX11 vs. Perjeta in Healthy Chinese Male SubjectsCompletedNCT04411550Phase 1
• Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck TumorsActive, not recruitingNCT04297995Phase 2
• Unipolar Microplasma Radiofrequency Device: In-vivo Histologic StudyWithdrawnNCT04153071Not applicable
• A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard ChemotherapyStatus unknownNCT04150575Phase 2
• A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric CancerStatus unknownNCT04139135Phase 3
• A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLCActive, not recruitingNCT04033354Phase 3
• A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) PatientsStatus unknownNCT03973112Phase 2
• A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)Status unknownNCT03958890Phase 3
• A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT03952403Phase 3
• Study of FCN-437c in Patients With Advanced Solid TumorsCompletedNCT03951116Phase 1
• ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast CancerCompletedNCT03950570Phase 1/2
• Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.CompletedNCT03944499Phase 1
• MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)SuspendedNCT03932253Phase 1
• Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2CompletedNCT03916094Phase 1
• Compare Pharmacokinetic, Safety, Tolerability and Immunogenicity of HLX12 and Ramucirumab in Healthy Male Adult SubjectsTerminatedNCT03863587Phase 1
• A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid TumorsStatus unknownNCT03757936Phase 1
• A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AMLTerminatedNCT03690154Phase 1
• A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid TumorsCompletedNCT03588650Phase 1
• The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors.CompletedNCT03577704Phase 1/2
• Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid ArthritisCompletedNCT03522415Phase 3
• A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRCCompletedNCT03511963Phase 3
• Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX04 Versus Avastin® in Healthy Male SubjectsCompletedNCT03483649Phase 1
• Phase I Study of HLX3 vs Adalimumab in Chinese Healthy SubjectsCompletedNCT03357939Phase 1
• A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDsCompletedNCT03355872Phase 1/2
• Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque PsoriasisCompletedNCT03316781Phase 3
• A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell LymphomasCompletedNCT03218072Phase 1
• Pro00019086 - Ultra Circumference ReductionStatus unknownNCT03115944Not applicable
• Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCLCompletedNCT02787239Phase 3
• Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female SubjectsCompletedNCT02747641Not applicable
• FiO2 in Chronic Obstructive Pulmonary Disease (COPD) Patient Normobaric O2 Versus NIVCompletedNCT02599246
• A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell LymphomaCompletedNCT02584920Phase 1/2
• A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(U.S. and German Sourced) in Healthy Chinese Male SubjectsCompletedNCT02581748Phase 1
• Epidermal Delivery of Ani-Aging IngredientsStatus unknownNCT01847066Not applicable
• Fractional Ablative Radiofrequency for the Treatment of Acne Scars and WrinklesCompletedNCT01645345Not applicable
• Target Volume Mode Controlled Ventilator in Obesity Hypoventilation SyndromeWithdrawnNCT01104610Not applicable
• The Treatment of Acne Vulgaris With Radiofrequency DeviceWithdrawnNCT00441805Not applicable

← Fosun Pharma overview and focus areas